 Beam Therapeutics Inc NASDAQ: BEAM acquires Guide Therapeutics GuideTx, a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for 120 million upfront. GuideTx shareholders could also yield up to 320 million more in milestone payments. 